

CITATION REPORT

List of articles citing

Angiogenesis in urological malignancy: prognostic indicator and therapeutic target

DOI: 10.1046/j.1464-410x.1999.00018.x

BJU International, 1999, 83, 535-55; quiz 555-6.

Source: <https://exaly.com/paper-pdf/32965484/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
25	New developments in the pharmacological management of prostate cancer. <i>BJU International</i> , 2000 , 85 Suppl 2, 31-7	5.6	11
24	Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. <i>BJU International</i> , 2000 , 85, 276-80	5.6	46
23	Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. <i>Urologic Clinics of North America</i> , 2000 , 27, 191-7	2.9	17
22	Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2001 , 35, 437-52		56
21	Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. <i>Molecular and Cellular Endocrinology</i> , 2002 , 197, 239-50	4.4	87
20	The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. <i>British Journal of Cancer</i> , 2002 , 86, 1276-82	8.7	95
19	The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. <i>Clinical Prostate Cancer</i> , 2003 , 2, 153-9		18
18	Angiogenesis and Histologic Scoring in Prostatic Carcinoma: A Valuable Cost Effective Prognostic Indicator. <i>UroOncology</i> , 2004 , 4, 139-143		
17	Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2532-9	2.2	276
16	Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy. <i>Cancer Gene Therapy</i> , 2005 , 12, 257-67	5.4	29
15	Antiangiogenesis: a possible treatment option for prostate cancer?. <i>Clinical Genitourinary Cancer</i> , 2005 , 4, 197-202	3.3	8
14	Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. <i>Prostate</i> , 2005 , 62, 364-73	4.2	57
13	Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2113; author reply 2113-4	2.2	10
12	Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2005 , 5, 188-96	3.8	95
11	The use of thalidomide in androgen-independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 246-9	2.8	12
10	Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. <i>BJU International</i> , 2000 , 86, 80-6	5.6	33
9	Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: the value of diagnostic predictors of prostate cancer. <i>BJU International</i> , 2000 , 86, 58-64	5.6	57

8	Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO cells. <i>Annals of Biomedical Engineering</i> , 2007 , 35, 605-14	4.7	13
7	Hormone-refractory prostate cancer responding to bevacizumab. <i>International Journal of Urology</i> , 2008 , 15, 754	2.3	4
6	Evaluation of selected growth factor expression in canine spirocercosis (<i>Spirocerca lupi</i>)-associated non-neoplastic nodules and sarcomas. <i>Veterinary Parasitology</i> , 2010 , 174, 257-66	2.8	14
5	Association of mast cells with microvessel density in urothelial carcinomas of the urinary bladder. <i>Annals of Diagnostic Pathology</i> , 2012 , 16, 1-6	2.2	11
4	RNA interference-mediated inhibition of survivin and VEGF in pancreatic cancer cells in vitro. <i>Molecular Medicine Reports</i> , 2013 , 7, 1651-5	2.9	9
3	Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. <i>British Journal of Pharmacology</i> , 2014 , 171, 5462-90	8.6	64
2	Antiangiogenic activity of 2-formyl-8-hydroxy-quinolinium chloride. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 80, 145-150	7.5	4
1	Grundlagen der Tumorbiologie. 2000 , 27-35		